Nakano Naomi, Hiruma Masataro, Shiraki Yumi, Chen Xuejun, Porgpermdee Sarawan, Ikeda Shigaku
Department of Dermatology, Juntendo University School of Medicine, Juntendo, Tokyo, Japan.
J Dermatol. 2006 Nov;33(11):753-8. doi: 10.1111/j.1346-8138.2006.00176.x.
We performed a pilot study to assess the safety and efficacy of pulse therapy with terbinafine tablets in 66 patients with dermatophyte onychomycosis. One pulse consisted of oral terbinafine tablets (500 mg/day) given for 1 week followed by a 3-week interval. Topical 1% terbinafine cream was applied daily. The number of pulses was determined by the extent of improvement in the affected nails and by the patient's requests, up to a maximum of six pulses. Efficacy was assessed based on both clinical and mycological examinations 1 year after treatment initiation. We observed a complete cure in 51 patients (77.3%), marked improvement in five patients (7.6%), improvement in five patients (7.6%) and slight improvement in one patient (1.5%). Four patients (6.0%) showed no change. In the patients who were completely cured, the average number of pulses used was 3.7 +/- 1.4 pulses and the treatment duration was 3.3 +/- 1.6 months. Nine patients experienced adverse effects, consisting of gastrointestinal disturbance (eight patients) and drug-induced eruption (one patient). There were no abnormal findings in the laboratory tests, including liver function tests. In summary, terbinafine pulse therapy in combination with topical application of terbinafine cream appeared safe and effective in this pilot study.
我们进行了一项初步研究,以评估特比萘芬片脉冲疗法对66例皮肤癣菌性甲真菌病患者的安全性和有效性。一个脉冲疗程包括口服特比萘芬片(500毫克/天),服用1周,随后间隔3周。每天外用1%特比萘芬乳膏。脉冲疗程的次数根据患甲的改善程度和患者的要求确定,最多为6个脉冲疗程。在开始治疗1年后,根据临床和真菌学检查评估疗效。我们观察到51例患者(77.3%)完全治愈,5例患者(7.6%)显著改善,5例患者(7.6%)改善,1例患者(1.5%)轻微改善。4例患者(6.0%)无变化。在完全治愈的患者中,平均使用的脉冲疗程数为3.7±1.4个,治疗持续时间为3.3±1.6个月。9例患者出现不良反应,包括胃肠道不适(8例)和药物性皮疹(1例)。包括肝功能检查在内的实验室检查未发现异常结果。总之,在这项初步研究中,特比萘芬脉冲疗法联合外用特比萘芬乳膏似乎是安全有效的。